Bright Minds Biosciences Inc. (DRUG) Fair Value 2026

DRUG · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 8 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-07-15, Bright Minds Biosciences Inc. (DRUG) trades at $75.92, approximately 120% above CirclFi’s Bayesian DCF fair value of $34.45. QOC: 4.7/10. Value Trap Risk: 12/100 (SAFE). 8/13 models active.

Key Facts

Ticker
DRUG
Price
$75.92
Quality Score
4.7/10
Value Trap Risk
12/100
Models Active
8/13
Last Updated
Strength: 8 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.7/10 signals weak fundamentals

Is Bright Minds Biosciences Inc. (DRUG) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Bright Minds Biosciences Inc. (DRUG) appears overvalued as of : the median of 8 independent fair value estimates is $8.96, 88.2% below the current price of $75.92. Estimates range from $1.31 to $75.49. DRUG scores 4.7/10 on fundamental quality and 12/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bright Minds Biosciences Inc. Stock in 2026? →

Valuation Matrix

8 Intrinsic Value Models vs. Current Price ($75.92)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $34.45 -54.6%
CUCE Ensemble
Low Conviction
 $16.50 -78.3%
First Chicago
Low Conviction
 $1.31 -98.3%
PWERM
Medium Conviction
 $75.49 -0.6%

Unlock the Full Matrix

Access 4 additional models including Dynamic NAV, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is Bright Minds Biosciences Inc. (DRUG) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bright Minds Biosciences Inc.'s intrinsic value is estimated at $21.96. Trading at its current price of $75.92, the valuation engine raises significant caution: 7 of 8 models flag downside risk, projecting an average implied return of -71.1%. The most optimistic model, PWERM, places fair value at $75.49 (-0.6%), while Sentiment SOTP — the most conservative — estimates $1.31 (-98.3%). This +97.7% gap reflects genuine analytical uncertainty about Bright Minds Biosciences Inc.'s intrinsic worth.

What Do the Models Say About DRUG?

8 of 13 models are currently active for DRUG. All 8 active models suggest the stock trades above fair value. The Bayesian DCF estimates DRUG's intrinsic value at $34.45, implying -54.6% downside from the current price. See which stocks rank higher →

How Does DRUG Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, DRUG ranks #254 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

Bright Minds Biosciences Inc.'s positioning within the Pharmaceutical Preparations segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is DRUG a Value Trap?

CirclFi's Value Trap algorithm assigns DRUG a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Bright Minds Biosciences Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Bright Minds Biosciences Inc. earns a quality score of 4.7/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +97.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every DRUG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across DRUG's 8 active models, average confidence is 8%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bright Minds Biosciences Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Bright Minds Biosciences Inc.

What is Bright Minds Biosciences Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Bright Minds Biosciences Inc. (DRUG) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $34.45. The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is DRUG overvalued or undervalued right now?

At $75.92, 0 of 8 active models suggest DRUG may be undervalued, while 8 indicate potential overvaluation. The median of all 8 fair value estimates is $8.96, 88.2% below the current price of $75.92 — a consensus view that DRUG is overvalued. The assessment depends on which methodology best fits Bright Minds Biosciences Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 4.7 mean for DRUG?

Bright Minds Biosciences Inc.'s QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on DRUG?

CirclFi analyzes DRUG with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Is DRUG a value trap in 2026?

Bright Minds Biosciences Inc.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Bright Minds Biosciences Inc. (DRUG) has a median fair value of $8.96 — 88.2% below the current price of $75.92 — as of 2026-07-15.” Source: circlfi.com/stock/DRUG/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on DRUG.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access